Sökning: onr:"swepub:oai:gup.ub.gu.se/330517" >
New therapeutic tar...
New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023
-
Kanai, A. (författare)
-
Chakrabarty, B. (författare)
-
- Winder, Michael, 1980 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology
-
visa fler...
-
Hashim, H. (författare)
-
Wein, A. (författare)
-
Abrams, P. (författare)
-
Fry, C. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2023
- 2023
- Engelska.
-
Ingår i: Neurourology and Urodynamics. - 0733-2467.
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- AimsBenign prostatic enlargement (BPE) can impact lower urinary tract function due to its potential progression to benign prostatic obstruction (BPO). Treatment options include removal of the obstruction by surgery or through use of therapeutics designed to slow growth or reduce tissue stress imposed by muscular stromal components. Inflammation and development of fibrosis can also raise intrinsic tissue stress within the gland, further impacting obstruction. Outflow tract obstruction can also impact emission and ejaculation if the obstruction persists.MethodsThis review summarizes an ICI-RS think tank considering novel drug treatments that might address BPO caused by progressive development of BPE, as well as manage decompensation changes to bladder function.ResultsTopics included recent advances in our understanding of pathological changes occurring to the prostate and other lower urinary tract tissues during progressive development of BPE, and how prevention or reversal might benefit from the identification of novel drug targets. These included contractile properties of prostatic tissues, the impact of BPE and its effects on bladder function, the deposition of intramural fibrotic tissue with protracted BPO, the role of inflammation in the development of BPE and its progression to BPO. In particular, we discussed current therapeutic options for treating BPE/BPO, and new therapeutic targets, what they treat and their advantage over current medications.ConclusionSeveral new drug targets were identified, including soluble guanylate cyclase (sGC), the receptor for nitric oxide (NO center dot), and sGC activators that promotes sGC-mediated cGMP production when sGC is inactivated and unresponsive to NO center dot.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- benign prostatic enlargement (BPE)
- benign prostatic obstruction (BPO)
- detrusor overactivity (DO)
- inflammation
- sGC activators
- soluble
- guanylate cyclase (sGC)
- therapeutics
- urinary-tract symptoms
- smooth-muscle-cells
- bladder
- hyperplasia
- inflammation
- pathology
- light
- men
- Urology & Nephrology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas